See more : CJW International CO., LTD. (5301.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Anterogen.Co.,Ltd. (065660.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anterogen.Co.,Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Hsin Sin Textile Co., Ltd. (4406.TWO) Income Statement Analysis – Financial Results
- Zhongxing Tianheng Energy Technology (Beijing) Co.,Ltd. (600856.SS) Income Statement Analysis – Financial Results
- Bitech Technologies Corporation (BTTC) Income Statement Analysis – Financial Results
- Huntington Bancshares Incorporated (HBANL) Income Statement Analysis – Financial Results
- China Greatwall Technology Group Co., Ltd. (000066.SZ) Income Statement Analysis – Financial Results
Anterogen.Co.,Ltd. (065660.KQ)
About Anterogen.Co.,Ltd.
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.50B | 6.59B | 8.12B | 4.15B | 4.15B | 3.61B | 5.36B | 4.90B | 3.53B | 1.83B |
| Cost of Revenue | 3.83B | 3.97B | 4.25B | 2.41B | 2.49B | 1.92B | 2.11B | 1.39B | 1.18B | 796.47M |
| Gross Profit | 2.67B | 2.62B | 3.87B | 1.74B | 1.66B | 1.69B | 3.25B | 3.50B | 2.35B | 1.04B |
| Gross Profit Ratio | 41.02% | 39.70% | 47.68% | 41.97% | 40.04% | 46.77% | 60.69% | 71.54% | 66.59% | 56.58% |
| Research & Development | 5.38B | 4.66B | 4.19B | 4.01B | 2.53B | 1.87B | 1.30B | 1.55B | 907.75M | 1.14B |
| General & Administrative | 209.62M | 804.51M | 227.18M | 117.72M | 154.99M | 143.46M | 196.39M | 198.24M | 142.40M | 178.98M |
| Selling & Marketing | 521.64M | 317.07M | 436.78M | 286.52M | 261.46M | 223.18M | 248.14M | 280.26M | 294.19M | 226.55M |
| SG&A | 731.25M | 1.12B | 663.96M | 404.23M | 416.45M | 366.64M | 444.52M | 478.50M | 436.59M | 405.53M |
| Other Expenses | 1.63B | 239.11M | 144.41M | 26.11M | -235.53M | 9.32M | 143.21K | -49.81M | -49.29M | -55.31M |
| Operating Expenses | 7.74B | 7.26B | 6.50B | 5.46B | 4.57B | 4.13B | 3.35B | 3.38B | 2.47B | 2.62B |
| Cost & Expenses | 11.60B | 11.24B | 10.75B | 7.86B | 7.06B | 6.05B | 5.45B | 4.78B | 3.65B | 3.42B |
| Interest Income | 1.98B | 990.05M | 339.27M | 168.44M | 900.72M | 664.78M | 330.76M | 291.14M | 129.91M | 233.97M |
| Interest Expense | 1.53B | 1.69B | 1.24B | 315.43M | 1.09B | 1.60B | 61.05M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 830.37M | 763.08M | 936.43M | 556.65M | 282.91M | 589.49M | 390.86M | 310.85M | 291.95M | 263.58M |
| EBITDA | -437.82M | -4.39B | 1.62B | -3.50B | -2.36B | 1.26B | 898.64M | 682.51M | 171.22M | -1.32B |
| EBITDA Ratio | -6.74% | -33.89% | -16.10% | -46.07% | -27.82% | -28.96% | 10.28% | 9.37% | 4.85% | -72.13% |
| Operating Income | -5.07B | -4.65B | -2.62B | -3.71B | -2.91B | -2.44B | -96.07M | 120.71M | -120.73M | -1.59B |
| Operating Income Ratio | -78.06% | -70.52% | -32.31% | -89.46% | -70.11% | -67.73% | -1.79% | 2.47% | -3.42% | -86.45% |
| Total Other Income/Expenses | 2.23B | -2.66B | 2.07B | -661.35M | -1.29B | 1.51B | 542.81M | 45.17M | 62.42M | 170.01M |
| Income Before Tax | -2.84B | -6.85B | -553.98M | -4.38B | -4.05B | -932.52M | 446.74M | 371.66M | -58.31M | -1.42B |
| Income Before Tax Ratio | -43.70% | -103.93% | -6.82% | -105.39% | -97.64% | -25.85% | 8.34% | 7.59% | -1.65% | -77.18% |
| Income Tax Expense | 3.00 | -12.97M | 158.97M | 1.04B | 303.26M | 29.24M | -27.80M | -264.10M | -129.91M | -960.01K |
| Net Income | -2.84B | -6.84B | -553.98M | -4.38B | -4.05B | -961.76M | 446.74M | 371.66M | -58.31M | -1.42B |
| Net Income Ratio | -43.70% | -103.73% | -6.82% | -105.39% | -97.64% | -26.66% | 8.34% | 7.59% | -1.65% | -77.18% |
| EPS | -291.93 | -705.88 | -59.45 | -481.12 | -469.96 | -114.00 | 57.00 | 50.00 | -9.00 | -218.00 |
| EPS Diluted | -291.93 | -705.88 | -59.45 | -464.35 | -468.23 | -111.92 | 24.00 | 50.00 | -9.00 | -218.00 |
| Weighted Avg Shares Out | 9.73M | 9.69M | 9.32M | 9.09M | 8.62M | 8.44M | 7.84M | 7.39M | 6.48M | 6.49M |
| Weighted Avg Shares Out (Dil) | 9.73M | 9.69M | 9.32M | 9.42M | 8.65M | 8.59M | 7.92M | 7.43M | 6.48M | 6.49M |
Source: https://incomestatements.info
Category: Stock Reports